Volume 13, Issue 2

Avascular necrosis (AVN) is the death of bone tissue due to a loss of blood supply, therefore also called as osteonecrosis ischemic bone necrosis. Treatment includes physiotherapy, surgery and medication as NSAIDs. All the treatment procedures are cost worthy and prognosis is poor .In this case main aim to evaluate the efficacy of Ayurvedic procedures in the conservative management of AVN of the femoral head. In this present case a 48yr old male was diagnosed with AVN Of bilateral hip joint associated with osteoarthritis of hip ,was managed with Udvartana ,Shashtishali Pind Sweda ,Kati Vasti and Manjishthadi Tiktaksheer Vasti .Patients was observed for symptomic improvements based on signs and symptoms before and after treatment. Observations/Results: The results were encouraging. The therapy provided marked improvements in the gait,pain,tenderness. Conservative management of AVN through Ayurvedic principles provides significant relief in sign and symptoms and improves quality of life. Key –words: Avascular necrosis,Asthi-Majjagata Vata,Manjishtadi Tiktaksheer Vasti, Shastishali Pinda Sweda.

Kanchnar (Bauhinia variegate) is tree growing in different parts of India. It is known to have analgesic and anti-inflammatory properties. Kanchnar's anti-inflammatory and antioxidant characteristics encourage the growth of new skin cells, which aids in wound healing. Kanchnar is available in the market as a variety of dosage forms, including churna, kashay, ointment, pills, topical gel etc. Prior to administration, standardization of herbal products is crucial for ensuring their quality. In light of this, the current study involved quantification of lupeol, an active marker found in kanchnar (Bauhinia variegate) bark and its two commercially available formulations. Bark extraction was done using maceration. The mobile phase was optimized and locating agent was used to visualize lupeol.

Polycystic ovarian syndrome [PCOS] is a hormonal disorder causing enlarged ovaries with small cysts on the outer edges. Between 5% and 10% of women between 15 and 44, or during the years you can have children, have PCOS. Most women find out they have PCOS in their 20s and 30s, when they have problems getting pregnant and see their doctor. But PCOS can happen at any age after puberty. Causes : The cause of polycystic ovary syndrome isn’t well understood, but may involve a combination of genetic and environmental factors. Symptoms: The symptoms of PCOS are trouble conceiving or infertility, mood changes, acne, fatigue, insulin resistance, high testosterone levels, male pattern baldness thinning hair, irregular or missed periods, low sex drive, ovarian cysts, weight changes and trouble losing weight, excessive body hair growth, etc. Diagnosis: PCOS can be diagnosed by androgen excess, ovulatory dysfunction, thyroid dysfunction, hyperandrogenism, hyperandrogenemia, menstrual cycle irregularity, ovarian dysmorphology. Treatment : The treatment of PCOS can be done by healthy eating, exercising and losing weight, blood sugar controlling, reducing stress and anxiety, anti - inflammatory treatment, eliminating toxins, taking vitamins, etc. Pathophysiology: The complex Pathophysiology of PCOS involves the interaction of genetic and epigenetic changes, primary ovarian abnormalities, neuroendocrine alterations, and endocrine and metabolic modifiers such as anti-Mullerian hormone, hyperinsulinemia, insulin resistance, adiposity, and adiponectin levels. There are several herbal formulations which help in reducing cysts formed due to PCOS. REERENCES: Aziz R., Woods S.K., Renya R., et al. The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population. JCEM,2004; 89(6): 2745-2749. Ferriman D., Gallwey D.J., Clinical Assessment of Body Hair Growth in Women, JCEM,1961; 21(11): 1440-1447. Hart R., Franks S., Definitions, Prevalence and Symptoms of Polycystic Ovaries and Polycystic Ovary Syndrome. JCEM,2004; 18(5): 671-683 Ibanez L., Ferrer A., et al. Insulin Sensitization Early After Menarche Prevents Progression from Precocious Pubarche to Polycystic ovary Syndrome. The Journal of Pediatrics,2004; 144(1): 23-29 Hickey M., Doherty DA., et al. Clinical Ultrasound and Biochemical features of Polycystic ovary Syndrome in Adolescents: implications for Diagnosis. Human Reproduction,2011; 26(6): 1469-1477 Hart R., Norman R., Polycystic ovarian syndrome-prognosis and outcomes. Best practice and research clinical obstetrics and gynaecology,2006; 20(5): 751-778 Balen A., Rajkowha M., Polycystic ovary syndrome-A systemic disorder? Best practice and research clinical obstetrics and gynaecology,2003; 17(2): 263-274 Wild RA., Long term health consequnces of PCOS. Human reproduction update,2002; 8: 231-241 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group., Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). NIH,2004; 19(1): 41-47 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group., Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). NIH,2004; 81(1): 19-25 Azziz R., PCOS: A diagnostic challenge, NIH,2004; 8(6): 644-648 Deng Y., Zhou H., et al. Effect of Diane-35 on polycystic ovarian syndrome of Different Subtypes. Open Journal of obstetrics and Gynecology,2014; 4(11): 377-384 Bozdag G., Yapici Z., et al. Prevalence, phenotype and cardio metabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human reproduction,2012; 27(10): 3067-3073 Agrawal R., Sharma S., et al. Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women. Fertility and Sterility,2004; 82(5): 1352-1357 Ehrmann DA., Barnes RB., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care,1999; 22(1): 141-146 Norman RJ., Masters L., et al. Relative risk of conversion from norm glycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction,2001; 16(9): 1995-1998 Troisi R., Potischman N., et al. Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. International Journal of Epidemiology,2003; 32(3): 455-460 Eilting MW., Korsen TJM., et al. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Human Reproduction,2001; 16(3): 556-560 Cussons AJ., Watts GA., et al. cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis,2006; 185(2): 227-239 Teede HJ., Hutchison S., et al. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine, Stepto Nk., Cassar S., et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycemic–hyperinsulaemic clamp. Human Reproduction,2013; 28(3): 777-784 Meyer C., McGrath BP., et al. Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome. Diabetes Care,2007; 30(3): 471-478 Moran LJ., Misso ML., et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update,2010; 16(4): 347-363 Fauser BC., Tarlatzis BC., et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility,2012; 97(1): 28-38 Veltman-Verhulst SM., Boivin J., et al. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Human Reproduction Update,2012; 18(6): 638-651 Jedel E., Waern M., et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Human Reproduction,2010; 25(2): 450-456 Mansson M., Holte J., et al. Women with polycystic ovary syndrome are often depressed or anxious—A case control study. Psychoneuroendocrinology,2008; 33(8): 1132-1138 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. 2004; 81(1): 19-25 Azziz R., Carmina E., et al. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. JCEM,2006; 91(11): 4237-4245 Escobar-Morreale HF., Sancho J., et al. The Polycystic Ovary Syndrome Associated with Morbid Obesity May Resolve after Weight Loss Induced by Bariatric Surgery. JCEM,2005; 90(12): 6364-6369 Longcope C., Adrenal and gonadal androgen secretion in normal females. 1986; 15(2): 213-228 Pasquali R., Casimirri F., The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clinical Endocrinology,1993; 39(1): 1-16 Rosner W., Auchus R., et al. Utility, Limitations, and Pitfalls in Measuring Testosterone: An Endocrine Society Position Statement. JCEM,2007; 92(2,1): 405-413 Piltonen T., Koivunen R., et al. Ovarian and adrenal steroid production: regulatory role of LH/HCG. Human Reproduction,2002; 17(3): 620-624 Lasley BL., Santoro N., et al. The Relationship of Circulating Dehydroepiandrosterone, Testosterone, and Estradiol to Stages of the Menopausal Transition and Ethnicity. JCEM,2002; 87(8,1): 3760-3767 Piltonen T., Koivunen R., et al. Ovarian Age-Related Responsiveness to Human Chorionic Gonadotropin. JCEM,2003; 88(7,1): 3327-3332 Giallauria F., Palomba S., et al. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. Clinical Endocrinology,2008; 68(1): 88-93 Tekin G., Tekin A., et al. Altered autonomic neural control of the cardiovascular system in patients with polycystic ovary syndrome. International of Journal of Cardiology,2008; 130(1): 49-55 Yildirir A., Aybar F., et al. Heart Rate Variability in Young Women with Polycystic Ovary Syndrome. Annals of non-invasive Electrocardiology,2023; 28(1): 306-312 Sverrisdottir YB., Mogren T., et al. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab,2008; 294(3): 76-81 Graf MJ., Richards CJ., et al. THE INDEPENDENT EFFECTS OF HYPERANDROGENAEMIA, HYPERINSULINAEMIA, AND OBESITY ON LIPID AND LIPOPROTEIN PROFILES IN WOMEN. Clinical Endocrinology,1990; 33(1): 119-131 Hoeger k., Davdison K., et al. The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials. JCEM,2008; 93(11): 4299-4306 R Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction,2004; 19(1): 41-47 Adams J., Polson DW., Franks S., Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed),1986; 293(6543): 355-359 Franks S., Gharani N., et al. The genetic basis of polycystic ovary syndrome. Human Reproduction,1997; 12(12): 2641-2648 Franks S., McCarthy M., Genetics of ovarian disorders: polycystic ovary syndrome. Rev Endocr Metab Disord,2004; 5(1): 69-76 Vink JM., Sadrzadeh S., et al. Heritability of polycystic ovary syndrome in a Dutch twin-family study. JCEM,2006; 91(6): 2100-2104 Dunaif A., Finegood DT., Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. JCEM,1996; 81(3): 942-947 Corbould A., Kim YB., et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab, 2005; 288(5): 1047-1054 Svendsen PF., Nilas L., et al. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Hum Reprod,2008; 23(9): 2113-2121 Graham H., Francis B., et al. Socioeconomic lifecourse influences on women's smoking status in early adulthood. Journal of Epidemiology and Community Health,2006; 60(3): 228-233 Barkley GS., Factors influencing health behaviors in the National Health and Nutritional Examination Survey, III (NHANES III). Soc Work Health Care,2008; 46(4): 57-79 Thurston RC., Kubzansky LD., et al. Is the association between socioeconomic position and coronary heart disease stronger in women than in men? Am J Epidemiol,2005; 162(1): 57-65 Martorell R., Khan Lk., Grummer-strawn LM., Obesity in women from developing countries. Eur J Clin Nutr,2000, 54(3): 247-252 Kumar apeli V., Seneviratne R de A., et al. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol,2008; 168(3): 321-328 Rebar RW., Legro RS., et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.Fertil Steril,2012; 97(1): 28-38 BalenA H., Conway GS., et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod,1995; 10(8): 2107-2111 Ridker PM., Buring JE., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation,2003; 107(3): 391-39 Wehr E., Pilz S., Kopera D., Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.Eur J Endocrinol,2009; 61(4): 575-582 Porte D., Central Regulation of Energy Homeostasis: The Key Role of Insulin. Daibetes,2006; 55(2): 8155-8160 Azziz R., Carmina E., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. JCEM,2006; 91(11): 4237-4245 Yarak S., Bagatin E., et al. Hyperandrogenism and skin: polycystic ovary syndrome and peripheral insulin resistance. An Bras Dermatol,2005; 80(4): 395-410 Yarak S., Bagatin E., et al. Hyperandrogenism and skin: polycystic ovary syndrome and peripheral insulin resistance. An Bras Dermatol,2005; 80(4): 395-410 Buccola JM., Reynolds EE., Polycystic ovary syndrome: a review for primary providers. Primary care: Clinics in office practice,2003; 30(4): 697-710 Spinasanta S., Its time rename polycystic ovary syndrome. Endocrine Web for Health Care Professionals,2016; Nair R., PCOS and it’s ayurvedic treatment. Goyal A, Ganie MA, Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters : A Case Report and Literature Review. NIH,2018 ;10(7) Albu D, Albu A. The relationship between anti-Mullerian hormone serum level and body mass index in a large cohort of infertile patients. NIH, 2019; 63(1) : 157-163 Spinedi E, Cardinali DP. The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy. NIH, 2018. Puttabyatappa M, Padmanabhan V. Ovarian and Exta-Ovarian Mediators in the Development of Polycystic Ovary Syndrome. NIH, 2018 ; 61(4): 161-184. Polycystic Ovary Syndrome(PCOS): Causes, Signs, and Symptoms , LTA, 2021 Barbados Family Planning Association womenhealth.gov womenhealth.gov womenhealth.gov hopkinsmedicine.org Bulsara J., Patel P., Soni A., Acharya S. A review: Brief insight into Polycystic Ovarian Syndrome, Endocrine and Metabolic Science,2021;3 Knochenhauer E.S., Key T.J., Kahsar-Miller M. et.al. Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study, JCEM , 1998; 83(9): 3078–3082 Kandarakis E.V., Chryssa R.K., Bergiele A.T. et.al. A Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile. JCEM, 1999; 84(11): 4006–4011 Asuncion M, Calvo R.M., Millan J.L.et.al. A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain. JCEM, 2000; 85(7) : 2434–2438 Taylor A E, Polycystic ovary syndrome.Endocrinol Metab Clin North Am,1998; 27(4): 877-902 Legro R S ,Polycystic ovary syndrome: current and future treatment paradigms.Am J Obstet Gynecol ,1998; 179(6): 101-108 Taylor A.E., Mccourt B., Martin K.A. et.al. Determinants of Abnormal Gonadotropin Secretion in Clinically Defined Women with Polycystic Ovary Syndrome. JCEM, 1997; 82(7) : 2248–2256 Stein I F , Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol, 1935 ; 29 : 181-191 dreamstime.com Armanini D., Mattarello M.J., Fiore C., Bonanni G., Licorice reduces serum testosterone in healthy women, PubMed , 2004; 69(11-12) : 736-6 Grant P., Spearmint Herbal Tea has Significant Anti-androgen Effects in Polycystic Ovarian Syndrome. A Randomized Controlled Trial, PubMed, 2009 ; 24(2) : 186-8 netmeds.com pcosliving.com biomedpharmajournal.org indianexpress.com Kodipalli A., Devi S., Prediction of PCOS and mental health Using Fuzzy Interference and SVM. Front. Public Health, 2021; 9 Kallen A., Watson S., Polycystic Ovary Syndrome(PCOS): Symptoms, Causes and Treatment. Healthline, 2021 Neuzil A., What is Polycystic Ovary Syndrome(PCOS). AFM, 2014 zee5.com : 65 percent women in India unaware of PCOS symptoms; reveals survey conducted by OZiva Jain T., Negris O., Brown D. et.al. Characterization of polycystic ovary syndrome among Flo app users around the world. Reproductive Biology and Endocrinology,2021 ; 36 Kavitha, M. G. Devi, N. PuvaneswariClinical Presentation, Risk Assessment and Management of Polycystic Ovary Syndrome (PCOS). International Journal of Biomedical and Advance Research,2017 ;8 : 66-71 Robert L. R., David A.E., The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as functional Ovarian Hyperandrogenism Revisited .Endrocrine Society, 2016; 37(5) : 467-520 Ferreria SR, Motta AB. Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations.Curr Med Chem. 2018 ; 25(15): 1792-1804 Gambineri A, Laudisio D, Marocco C, Radellini S, Colao A, Savastano S., Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Female infertility: which role for obesity? Int J Obes Suppl., 2019; 9(1): 65-72 Le Donne M, Alibrandi A Giarrussso R, Lo Monaco I, Muraca U. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. Bvs , 2012 ; 64(1): 23-9

Bars (Leucoderma), is a very common skin disorder in which well-demarcated de-pigmented chalky white patches appear on various parts of the body. Although there are numerous treatment modalities exist in mainstream medicine, but all have their pitfalls and the problem of treatment remains. In Unani literature, bars is described as a chronic disease that has been effectively treated with various single and compound herbal preparations since Greco-Arab period. Unani physicians say that it is caused by unnecessary accumulation of abnormal phlegm. Renowned Unani physicians therefore advocated that the treatment of leucoderma should start with the removal of balgham-e-ghaleez from the body with an appropriate dose of Munzij and Mushil therapy. After Munzij and Mushil therapy, har mizaj drugs (hot temperament) along with specific dugs like Psoralea seeds (Psoralea corylifolia), Atrilal (Ammi majus), Fig (Ficus carica), China root (Smilax china), Ringworm plant (Cassiafora foetidalin), Sarphoka (Tephrosia purpurea), Barg-e-hina (Lawsonia inermis) are advocated for therapy. Direct sunlight exposure to lesion together with local applicants has an excellent effect as sunlight activates the pigmentation process. Our aim is to illustrate the concept and methods of treating bars mentioned by Unani Physicians, with the aim of providing inexpensive, effective, readily available, and comparatively safe drugs for treating bars and popularizing Unani medicine among people. In the light of the above discussion, we can conclude that the dissemination of knowledge about the extensive and efficient Unani herbs and general treatment principles applied by Unani scholars since ancient times will be extremely efficient in the treatment bars Key-word: Bars, Leucoderma, Melanin, Unani system of medicine, White patches

This is a case study of a 30 years old male patient with complaints of severe itching, wheals all over body, pain and burning sensation since last 07 years. This condition is known as sheetpitta in ayurveda which is very much similar to urticaria in modern science (an allergic condition of skin to a variety of exogenous and endogenous agents). Sheetpitta is a condition in which vata and kapha dosha gets vitiated due to exposure to cold and these two doshas vitiate pitta,that circulate all over the body producing symptoms such as ‘vratika danshvat shotha’(wheals over body), daha (burning sensation), kandu (itching). Any significant relief was not observed by the patient from conventional antihistamine therapies,omalizumab injections and steroids. The condition of this patient was managed with panchakarma procedures like vamana and virechana along with shaman aushadhi, which elicited remarkable improvement in subsiding the symptoms and reducing its recurrence rate. The patient was asked to monitor itching, hives and other symptoms daily for seven days. Before and after treatment urticaria activity score (UAS7) was accessed at each follow up. Quality of life showed remarkable improvement based on UAS7 score. Key –words:Sheetpitta, Urticaria, Omalizumab, Vamana, Virechan, Shamana, Shodhan, UAS7 score

People who have been infected with Covid-19virus, can experience long term effects from this infection which is referred as Post-Covid condition (PCC) or Long Covid. Covid -19 is a highly infectious disease that may leadto severe post covid complication like Bronchial Asthma(TamakaSwasa) in some patients. When it effects the lungs, Covid -19 can lead to symptoms such as coughing,wheezing and shortness of breath. Respiratory virus infection frequently exacerbate Bronchial Asthma. Ayurveda has mentioned Panchakarma therapies for the treatment of Bronchial Asthma (TamakaSwasa). In the present case, a 48 year old male patient visited OPD of Panchakarma Department, Himalayiya Ayurvedic P.G Medical College and Hospital ,Dehradun with complaints of acute shortness of breath, cough and chest congestion , the symptoms have worsened after he was infected with Covid 19 in April 2021. Patient was managed with Vamana karma,Nasya Karma and Nebulization procedure along with ShamanaChikitsa. Vamana Karma was performed with Madanphaldi Yoga. After Vamana,Nasya karmawith Anu Taila for 7 days and Nebulization with TulsiArka twice per day for 7 days was given. Swasakuthar Rasa, Swasakasachintamani Rasa along with NayopayamKasayam andKankasavawas given for 30 days. Vamana Karma,Nasya karma, Nebulization and ShamanaChikitsa procedure showed significant improvement in symptoms of Bronchial Asthma (TamakaSwasa).